Literature DB >> 12201521

Adenoviral-mediated transfer of a lysostaphin gene into the goat mammary gland.

W Fan1, K Plaut, A J Bramley, J W Barlow, D E Kerr.   

Abstract

As a step toward preventing and curing Staphylococcus aureus mastitis, an adenoviral-mediated gene transfer technique was used to enable mammary cells to synthesize and secrete lysostaphin, an anti-staphylococcal protein. A lysostaphin gene, modified for eukaryotic expression of the bioactive variant, Gln125,232-lysostaphin, was inserted into a replication deficient adenovirus by homologous recombination in 293 cells. The resulting adenoviral vector containing the modified lysostaphin gene (Ad-lys) was used to infect bovine mammary epithelial cells in vitro and caprine mammary cells in vivo. A similar adenoviral vector containing the Escherichia coli gene encoding beta-galactosidase (Ad-lacZ) was also evaluated. Transduction of cultured bovine cells by Ad-lacZ was confirmed by the presence of beta-galactosidase in fixed cells 48 h postinfection. Bovine cells transduced by Ad-lys secreted immunoreactive Gln125,232-lysostaphin (0.8 microg/ml) into media that had approximately 20% bioactivity compared with native lysostaphin. To evaluate transduction in vivo, udder halves of four nonlactating goats were exposed to 10(10) plaque-forming units (pfu) ofAd-lacZ by two intramammary infusions given 48 h apart. The animals were euthanized 24 h later, and extensive expression of beta-galactosidase was detected in cells lining the teat canals, with more moderate expression observed in adjoining mammary parenchyma. Udder halves of two other nonlactating goats were infused with 10(10) pfu of Ad-lys while contralateral udder halves received Ad-lacZ. The animals were euthanized 48 h postinfusion. In both animals, extensive expression of beta-galactosidase was detected in Ad-lacZ exposed teats. Immunoreative Gln125,232-lysostaphin was detectable in secretions from Ad-lys exposed glands 24 h postinfusion, increasing to approximately 1 microg/ml at 48 h postinfusion. As with cultured bovine mammary epithelial cells, the bioactivity of goat-derived Gln125,232-lysostaphin was approximately 20% of native lysostaphin. These results demonstrate that an adenoviral vector can be used to introduce a gene into the ruminant mammary gland, enabling the secretion of a bioactive form of lysostaphin.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12201521     DOI: 10.3168/jds.S0022-0302(02)74244-6

Source DB:  PubMed          Journal:  J Dairy Sci        ISSN: 0022-0302            Impact factor:   4.034


  6 in total

Review 1.  The transgenic animal platform for biopharmaceutical production.

Authors:  L R Bertolini; H Meade; C R Lazzarotto; L T Martins; K C Tavares; M Bertolini; J D Murray
Journal:  Transgenic Res       Date:  2016-01-28       Impact factor: 2.788

2.  Intramammary expression and therapeutic effect of a human lysozyme-expressing vector for treating bovine mastitis.

Authors:  Huai-chang Sun; Fang-ming Xue; Ke Qian; Hao-xia Fang; Hua-lei Qiu; Xin-yu Zhang; Zhao-hua Yin
Journal:  J Zhejiang Univ Sci B       Date:  2006-04       Impact factor: 3.066

3.  Expression of lysostaphin in HeLa cells protects from host cell killing by intracellular Staphylococcus aureus.

Authors:  Marcus Klein; Martin Krönke; Oleg Krut
Journal:  Med Microbiol Immunol       Date:  2006-02-16       Impact factor: 3.402

4.  Adeno-associated-virus-mediated transduction of the mammary gland enables sustained production of recombinant proteins in milk.

Authors:  Stefan Wagner; Rosemary Thresher; Ross Bland; Götz Laible
Journal:  Sci Rep       Date:  2015-10-14       Impact factor: 4.379

5.  Design and High Expression of Non-glycosylated Lysostaphins in Pichia pastoris and Their Pharmacodynamic Study.

Authors:  Wenluan Shen; Na Yang; Da Teng; Ya Hao; Xuanxuan Ma; Ruoyu Mao; Jianhua Wang
Journal:  Front Microbiol       Date:  2021-03-18       Impact factor: 5.640

6.  Crystal structure of the antimicrobial peptidase lysostaphin from Staphylococcus simulans.

Authors:  Izabela Sabala; Elzbieta Jagielska; Philip T Bardelang; Honorata Czapinska; Sven O Dahms; Jason A Sharpe; Richard James; Manuel E Than; Neil R Thomas; Matthias Bochtler
Journal:  FEBS J       Date:  2014-08-01       Impact factor: 5.542

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.